Literature DB >> 15327950

The IL-10R2 binding hot spot on IL-22 is located on the N-terminal helix and is dependent on N-linked glycosylation.

Naomi J Logsdon1, Brandi C Jones, Jennifer C Allman, Lara Izotova, Barbara Schwartz, Sidney Pestka, Mark R Walter.   

Abstract

IL-22 is a class 2 alpha-helical cytokine involved in the generation of inflammatory responses. These activities require IL-22 to engage the cell surface receptors IL-22R1 and the low-affinity signaling molecule IL-10R2. IL-10R2 also interacts with five other class 2 cytokines: IL-10, IL-26, and the interferon-like cytokines IL-28A, IL-28B, and IL-29. Here, we define the IL-10R2 binding site on IL-22 using surface plasmon resonance (SPR) and site-directed mutagenesis. Surprisingly, the binding hot spot on IL-22 includes asparagine 54 (N54), which is post-translationally modified by N-linked glycosylation. Further characterization of the glycosylation reveals that only a single fucosylated N-acetyl glucosamine on N54 is required for maximal IL-10R2 binding. Biological responses of IL-22 mutants measured in cell-based luciferase assays correlate with the in vitro SPR studies. Together, these data suggest that IL-22 activity may be modulated via changes in the glycosylation state of the ligand during inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327950     DOI: 10.1016/j.jmb.2004.07.069

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  24 in total

Review 1.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

Review 2.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

3.  Structure of IL-22 bound to its high-affinity IL-22R1 chain.

Authors:  Brandi C Jones; Naomi J Logsdon; Mark R Walter
Journal:  Structure       Date:  2008-07-03       Impact factor: 5.006

Review 4.  Are circulating gonadotropin isoforms naturally occurring biased agonists? Basic and therapeutic implications.

Authors:  Brian J Arey; Francisco J López
Journal:  Rev Endocr Metab Disord       Date:  2011-12       Impact factor: 6.514

5.  Structure and mechanism of receptor sharing by the IL-10R2 common chain.

Authors:  Sung-Il Yoon; Brandi C Jones; Naomi J Logsdon; Bethany D Harris; Ashlesha Deshpande; Svetlana Radaeva; Brian A Halloran; Bin Gao; Mark R Walter
Journal:  Structure       Date:  2010-05-12       Impact factor: 5.006

6.  Structural and biophysical studies of the human IL-7/IL-7Ralpha complex.

Authors:  Craig A McElroy; Julie A Dohm; Scott T R Walsh
Journal:  Structure       Date:  2009-01-14       Impact factor: 5.006

Review 7.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2003-2004.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2009 Mar-Apr       Impact factor: 10.946

8.  Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family.

Authors:  Hans Henrik Gad; Christoffer Dellgren; Ole J Hamming; Susanne Vends; Søren R Paludan; Rune Hartmann
Journal:  J Biol Chem       Date:  2009-05-20       Impact factor: 5.157

9.  Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains.

Authors:  Mario de Oliveira Neto; José Ribamar Ferreira; Didier Colau; Hannes Fischer; Alessandro S Nascimento; Aldo F Craievich; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Biophys J       Date:  2007-11-16       Impact factor: 4.033

10.  IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis.

Authors:  Ken Sugimoto; Atsuhiro Ogawa; Emiko Mizoguchi; Yasuyo Shimomura; Akira Andoh; Atul K Bhan; Richard S Blumberg; Ramnik J Xavier; Atsushi Mizoguchi
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.